Axogen (AXGN) earnings report indicated -$0.08 in EPS and $31.04M in revenue. The company develops solutions for peripheral nerve regeneration and repair, while helping health care providers restore quality of life to patients. Its CEO, president, and chairman, Karen Zaderej, weighs in on what is next. The AXGN stock is up about 17% in 2021.
The Watch List
13 May 2021
SHARE
The Watch List
22 Feb 2022
The Watch List
01 Mar 2022
The Watch List
20 Apr 2022
The Watch List
01 Apr 2022
The Watch List
28 Apr 2022
Morning Trade Live
18 Feb 2022